PharmaSGP Holding SE
· ISIN: DE000A2P4LJ5
· EQS - adhoc news
Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News PharmaSGP Holding SE
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
06 August 2025 04:16PM
Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025
Ad-hoc announcement pursuant to Article 17 of the Regulation (EU) No. 596/2024
PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchange effective upon the expiry of August 11, 2025
Gräfelfing, August 6, 2025 – The Management Board of PharmaSGP Holding SE (“PharmaSGP”) has been informed today about the decision of the man...
PharmaSGP Holding SE
28 July 2025 05:04PM
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board and Supervisory Board on the public delisting tender offer by FUTRUE GmbH
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board and Supervisory Board on the public delisting tender offer by FUTRUE GmbH
Gräfelfing, July 28, 2025 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5, WKN: A2P4LJ) today published their joint reasoned statement pursuant to Sectio...
PharmaSGP Holding SE
24 July 2025 02:11PM
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders of PharmaSGP Holding SE
Ad-hoc announcement pursuant to Article 17 of the Regulation (EU) No. 596/2024
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders of PharmaSGP Holding SE
Gräfelfing, July 24, 2025 – FUTRUE GmbH informed PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) today that it holds more than 95% of the shares in PharmaSGP Holding SE in...
PharmaSGP Holding SE
18 July 2025 11:57AM
Acceptance period for FUTRUE GmbH’s public delisting tender offer underway
PharmaSGP Holding SE: Acceptance period for FUTRUE GmbH’s public delisting tender offer underway
Gräfelfing, July 18, 2025 – PharmaSGP Holding SE (ISIN: DE000A2P4LJ5 WKN: A2P4LJ) announces that the public delisting tender offer made by FUTRUE GmbH to the shareholders of PharmaSGP is open for acceptance.
Shareholders of PharmaSGP can tender their...
PharmaSGP Holding SE
11 July 2025 08:01AM
PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025
Publication of inside information in accordance with Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025
Gräfelfing, July 11, 2025 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has today decided, based on an evaluation of current data on business development c...
PharmaSGP Holding SE
26 June 2025 12:39PM
PharmaSGP Holding SE holds 2025 Annual General Meeting
PharmaSGP Holding SE holds 2025 Annual General Meeting
91.12% of the registered share capital was represented
Minimum dividend of €0.05 per dividend-bearing share resolved
Management Board reports on successful operational development in 2024; forecast for current fiscal year 2025 confirmed
Gräfelfing, June 26, 2025 – German OTC pharmaceutical ...
PharmaSGP Holding SE
18 June 2025 05:29PM
PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met
PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met
Gräfelfing, June 18, 2025 – PharmaSGP SE (ISIN: DE000A2P4LJ5) currently holds treasury shares representing approximately 4.06% of its share capital as a result of last year's share buyback. In order to make optimal use of the new authorization to acqu...
PharmaSGP Holding SE
10 June 2025 08:42AM
Conclusion of a delisting agreement and announcement of a delisting tender offer by FUTRUE GmbH
Publication of inside information pursuant to Art. 17 para. 1 of
Regulation (EU) 596/2014
Ad-hoc Notification
PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a delisting tender offer by FUTRUE GmbH
Gräfelfing, June 10, 2025. Today, PharmaSGP Holding SE (ISIN DE000A2P4LJ5 / WKN A2P4LJ) (“PharmaSGP”) entered into a...
PharmaSGP Holding SE
10 June 2025 08:35AM
Pharma SGP Holding SE; Bidder: Futrue GmbH
EQS-WpÜG: Futrue GmbH / Tender Offer
Tender Offer / Target company: Pharma SGP Holding SE; Bidder: Futrue GmbH
10.06.2025 / 08:35 CET/CEST
Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by EQS News - a service of EQS Group.
The bidder is solely responsible for the cont...
Futrue GmbH
15 May 2025 07:30AM
PharmaSGP continues its growth course in 2025
PharmaSGP continues its growth course in 2025
Gräfelfing, May 15, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE has made a successful start to 2025, achieving a 10.8% increase in revenues to €33.5 million in the first quarter based on preliminary, unaudited figures (prior-year quarter: €30.2 million). Compared to the previous y...
PharmaSGP Holding SE
15 April 2025 07:30AM
PharmaSGP with significant increase in revenues and EBITDA in 2024
PharmaSGP with significant increase in revenues and EBITDA in 2024
Gräfelfing, April 15, 2025 – Based on preliminary, unaudited figures, the German OTC pharmaceutical company PharmaSGP Holding SE significantly increased its revenues from 2023 by 17.5% to € 118.8 million in the 2024 financial year. The sole driver of the positive business developme...
PharmaSGP Holding SE
14 November 2024 07:30AM
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised
Gräfelfing, November 14, 2024 – In the third quarter of 2024, the German OTC pharmaceutical company PharmaSGP Holding SE was able to continue the dynamic business development of the first half of the year, generating revenues of €88.6 million in the first nin...
PharmaSGP Holding SE
05 November 2024 10:07AM
Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
Gräfelfing, November 05, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is announcing a change in the position of Chief Executive Officer (CEO). After more than seven years as CEO, Natalie Weigand informed the Supervisory Board today...
PharmaSGP Holding SE
05 November 2024 10:02AM
Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January ...
PharmaSGP Holding SE
01 October 2024 08:15AM
PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
PharmaSGP Holding SE has purchased 477,701 own sha...
PharmaSGP Holding SE
12 September 2024 08:15AM
PharmaSGP continues dynamic growth path in the first half of 2024
PharmaSGP continues dynamic growth path in the first half of 2024
Gräfelfing, September 12, 2024 – The German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path in the first half of 2024, achieving half-year revenues of €58.4 million based on preliminary, unaudited figures. This represents an increase of 17.4% compa...
PharmaSGP Holding SE
12 September 2024 08:10AM
PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE AD-HOC RELEASE.
Disclosure of an inside information acc. to Art. 17...
PharmaSGP Holding SE
27 June 2024 09:45AM
Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance
PharmaSGP Holding SE: Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance
89.74% of the share capital was represented; all agenda items were approved
Shareholders approve increased dividend distribution of €1.36 per dividend-bearing share
The appointment of Peter Gerckens ...
PharmaSGP Holding SE
21 June 2024 07:30AM
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
PharmaSGP expands the Management Board as of July 1, 2024 with Peter Gerckens as Chief Commercial Officer (CCO), a newly created position
Peter Gerckens will be responsible for international markets, sales and new businesses
Gräfelfing, June 21, 2024 – German OTC p...
PharmaSGP Holding SE
14 May 2024 07:30AM
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
Gräfelfing, May 14, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to €30.1 million (prior-year quarter: €24.0 mil...
PharmaSGP Holding SE
18 April 2024 08:31PM
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
Gräfelfing, April 18, 2024 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5) will propose to this year's Annual General Meeting ...
PharmaSGP Holding SE
16 April 2024 07:30AM
PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024
PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024
Gräfelfing, April 16, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the successful development of previous years in the 2023 financial year and exceeded the € 100 million revenues mark for the first time in the company's ...
PharmaSGP Holding SE
14 November 2023 07:30AM
PharmaSGP continues the profitable growth course of the previous quarters in the third quarter of 2023
PharmaSGP continues the profitable growth course of the previous quarters in the third quarter of 2023
Gräfelfing, November 14, 2023 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of the previous quarters in the third quarter of 2023. Based on preliminary, unaudited figures, quarterly revenues ...
PharmaSGP Holding SE
14 September 2023 07:30AM
PharmaSGP achieves top performance in the first half of 2023
PharmaSGP achieves top performance in the first half of 2023
Gräfelfing, September 14, 2023 – In the first half of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 49.7 million based on preliminary, unaudited results. This corresponds to an i...
PharmaSGP Holding SE
29 June 2023 07:30AM
Strong support at 2023 AGM for very successful business development
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
91.11% of share capital represented; all agenda items approved
Shareholders approve dividend distribution of EUR 0.49 per dividend-bearing share
In 2022, PharmaSGP had again achieved record revenues with significant increase in profitability
After strong y...
PharmaSGP Holding SE
29 June 2023 07:30AM
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
91.11% of share capital represented; all agenda items approved
Shareholders approve dividend distribution of EUR 0.49 per dividend-bearing share
In 2022, PharmaSGP had again achieved record revenues with significant increase in profitability
After strong y...
PharmaSGP Holding SE
10 May 2023 07:30AM
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
Gräfelfing, 10 May 2023 – In the first quarter of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters and achieved the highest level of quarterly revenue in the company’s history to date at € 2...
PharmaSGP Holding SE
10 May 2023 07:30AM
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
Gräfelfing, 10 May 2023 – In the first quarter of 2023, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters and achieved the highest level of quarterly revenue in the company’s history to date at € 2...
PharmaSGP Holding SE
19 April 2023 07:30AM
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
Gräfelfing, 19 April 2023 – The German OTC pharmaceutical company, PharmaSGP Holding SE (WKN A2P4LJ), remains on track for highly profitable growth. The Munich-based company posted the best set of figures in its history in financial year 2022, generating revenue of € 85.8...
PharmaSGP Holding SE
19 April 2023 07:30AM
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
Gräfelfing, 19 April 2023 – The German OTC pharmaceutical company, PharmaSGP Holding SE (WKN A2P4LJ), remains on track for highly profitable growth. The Munich-based company posted the best set of figures in its history in financial year 2022, generating revenue of € 85.8...
PharmaSGP Holding SE
15 March 2023 07:30AM
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year...
PharmaSGP Holding SE
15 March 2023 07:30AM
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year...
PharmaSGP Holding SE
14 March 2023 06:17PM
PharmaSGP Holding SE releases forecast for full year 2023
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE releases forecast for full year 2023
Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere...
PharmaSGP Holding SE
14 March 2023 06:17PM
PharmaSGP Holding SE releases forecast for full year 2023
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE releases forecast for full year 2023
Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere...
PharmaSGP Holding SE
20 February 2023 07:30AM
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac...
PharmaSGP Holding SE
20 February 2023 07:30AM
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac...
PharmaSGP Holding SE
03 January 2023 04:13PM
PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro
PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro
Gräfelfing, Germany, January 3, 2023 - The Management Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5, „PharmaSGP“) has decided today, with the approval of the Supervisory Board, utilizing the authorization of the General Meeting of May 28, 2020, to buy-back ...
PharmaSGP Holding SE
16 November 2022 07:30AM
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan...
PharmaSGP Holding SE
16 November 2022 07:30AM
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan...
PharmaSGP Holding SE
10 November 2022 04:59PM
PharmaSGP Holding SE raises forecast for FY 2022
PharmaSGP Holding SE raises forecast for FY 2022
Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati...
PharmaSGP Holding SE
10 November 2022 04:59PM
PharmaSGP Holding SE raises forecast for FY 2022
PharmaSGP Holding SE raises forecast for FY 2022
Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati...
PharmaSGP Holding SE
01 September 2022 07:30AM
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited...
PharmaSGP Holding SE
01 September 2022 07:30AM
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited...
PharmaSGP Holding SE
21 July 2022 07:29AM
PharmaSGP successfully secures financing of up to € 160 million
PharmaSGP successfully secures financing of up to € 160 million
Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r...
PharmaSGP Holding SE
21 July 2022 07:29AM
PharmaSGP successfully secures financing of up to € 160 million
PharmaSGP successfully secures financing of up to € 160 million
Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r...
PharmaSGP Holding SE
15 June 2022 04:59PM
PharmaSGP Holding SE successfully holds 2022 AGM
PharmaSGP Holding SE successfully holds 2022 AGM
- 91.07% of share capital represented
- Shareholders approve proposed dividend payment; all other agenda items approved by a clear majority
- Following record revenue in 2021, Management Board reports on growth prospects based on PharmaSGP platform
Gräfelfing, 15 June 2022 – PharmaSGP Holding SE ...
PharmaSGP Holding SE
17 May 2022 07:30AM
PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year
PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year
Gräfelfing, 17 May 2022 – In the first quarter of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path of the previous quarters and achieved another revenue record of € 20.6 million on the basis of preliminary, unaudited results. ...
PharmaSGP Holding SE
25 April 2022 07:30AM
PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
Gräfelfing, 25 April 2022 - After another record year, German pharmaceutical company PharmaSGP is targeting revenues of between 78 and 82 million euro for financial year 2022, up from 65.3 million euro in the year before, equating to planned growth of at least 19.5%....
PharmaSGP Holding SE
More PharmaSGP Holding SE related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 11 | 8th August 2025 | FUTRUE GmbH | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN